Emerald Health Therapeutics has completed planting at its indoor Québec facility, Verdélite, and expects to complete planting in the next days in the first of its two greenhouses in Metro Vancouver, allowing for transition into the commercial phase of these operations and a significant increase in quality cannabis production with approximately 7,500kg of product output targeted for these facilities in 2020.
"The 88,000 square foot indoor Verdélite facility consists of 21 grow rooms with precision-controlled environments and 16 processing rooms, which became fully licensed in October," the team with the company explains. "The growing area is equipped to produce 4,800 kg of high-quality craft cannabis annually, and Verdélite’s established packaging and processing lines are built to process the targeted production volume and a wide diversity of value-added products. Verdélite’s marketing strategy is focused on building differentiated brands with a unique Québec identity and targeting consumers seeking premium dried flower and other value-added cannabis products for both adult-use and health and wellness benefits."
"Emerald’s Metro Vancouver operation encompasses 156,000 square feet in two greenhouses, and 12 acres of outdoor cultivation area that became licensed in the summer," they further explain. "The first of its two 78,000 square foot greenhouses received its full cultivation license in October and organic certification in November. This facility will organically grow multiple strains of unique high-THC and high-CBD cannabis to expand Emerald’s product line and will be particularly focused on serving medical customers and adult-use consumers seeking health and wellness benefits."
“Our strategy to have multiple complementary operations is maturing and we are transitioning into commercial production in all our facilities,” said Riaz Bandali, President & Chief Executive Officer of Emerald. “As we move into full production, and with our nationwide distribution network in place and international market opportunities such as our recently announced Danish sales agreement, we expect sales of our differentiated Emerald cannabis products from these expanded facilities to start in the first quarter of 2020 and ramp up significantly through the year.”
For more information:
Emerald Health Therapeutics